BridgeBio PDUFA date set for Nov. 27, 2026

BridgeBio said the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, marking what officials described as the first major regulatory waypoint in the company’s current path from pipeline assets to commercial execution.

Alongside the FDA timing, the company outlined three planned product launches as it maps its next commercial steps. Officials said the schedule is expected to concentrate attention on near-term valuation catalysts linked to regulatory and clinical milestones, while noting that market reaction was still pending at the time of the update.

FDA target date becomes the first near-term milestone FDA target date becomes the first near-term milestone Officials said BridgeBio management framed the November 27 Officials said BridgeBio management framed the November 27, 2026 PDUFA date as the opening event in a sequence of pipeline-to-commercial milestones. The company linked the fixed decision date to later readouts and launch planning, positioning the date as a reference point for how upcoming events will be tracked. BridgeBio also pointed to factors it said support near-term priorities, according to officials. Those factors included Attruby growth, new kidney-protection data, and a cash boost reported for the quarter. RECLAIM‑HP readout window extends into early 2028 Officials said an efficacy readout from RECLAIM‑HP is expected within 18 months. Based on the company’s stated timing, they said that window would land in the first half of 2028. Officials added that the 18-month timeline was announced on August 11, 2026. Using that anchor date, they said a potential data arrival would be by February 11, 2028.

Approval and downside paths outlined around November 27

Officials said management described two scenarios around the FDA decision.

If the agency’s action on November 27 If the agency’s action on November 27, 2026 results in approval, management argues BridgeBio could accelerate its commercial rollout and move forward revenue recognition for the approved asset.

Officials said management also highlighted the contrasting risk: a negative outcome or a delay could push out launch timelines and extend cash-burn assumptions. They said this would raise financing risk under the company’s downside framing.

Investor attention on binary dates remains a key variable Officials said investors often treat regulatory decision dates as binary events in small-cap biotech, and equity pricing can shift around those outcomes. They said the company’s timetable is expected to sharpen focus on upcoming clinical and commercial milestones over the coming months.

While BridgeBio’s update set out a schedule pairing a fixed FDA action date with a later clinical readout window, officials noted the market’s response had not yet been reflected in the company’s communications at the time of the statement.